Once-daily tablet, CABOMETYX®▼(cabozantinib), approved by NICE as a first-line treatment for adult patients with Advanced Renal Cell Carcinoma (RCC) with intermediate or poor risk per the International Metastatic Renal Cell Carcinoma Database (IMDC) criteria
The UK affiliate of Ipsen has announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) on the use of cabozantinib in treatment-naïve adult patients with Advanced Renal Cell Carcinoma (RCC) with intermediate or poor risk.
Kidney cancer is the seventh most common cancer in the UK, responsible for around 12,600 new cases every year in the UK which equates to 34 cases every day. Up to 30% of all people are diagnosed when in the advanced stage of the disease. Over the last decade kidney cancer incidence has risen by nearly half (47%) and is projected to rise by 26% in the UK between 2014 and 2035. RCC is the most common form of kidney cancer, accounting for 75% of kidney cancer cases in the UK. Symptoms of RCC can include blood in the urine, a persistent pain in the side of the body, and a lump or swelling in the kidney area.
Dr Philip Savage, Consultant Medical Oncologist at Brighton and Sussex University Hospitals NHS Trust said: “The NICE decision is great news for patients and the kidney cancer community. Patients will now be able to access a much-needed additional treatment option to tackle this challenging illness, at an earlier stage. With proven clinical efficacy, including a demonstrable increase in progression-free survival, I believe cabozantinib has the potential to be considered the new standard of care for TKI therapy in aRCC in the UK.”
Nick Turkentine, CEO of Kidney Cancer UK said, “With over 12,600 new cases diagnosed every year in the UK, kidney cancer continues to rise with over 4,500 people losing their lives to the disease annually. This announcement strengthens the hand of medical professionals in England and Wales to treat first-line kidney cancer and offer hope of a positive future to thousands of patients. We are delighted by NICE’s decision to recommend access to cabozantinib as a first-line treatment option, in addition to its current approval for second-line therapy.”
Read the original article here